# A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430

> **NCT02319772** · PHASE1 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 94 (actual)

## Conditions studied

- Filovirus Infections
- Ebola Virus Infection

## Interventions

- **DRUG:** BCX4430
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02319772
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-04
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2016-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319772, "A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02319772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*